Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03033914
Title A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Hodgkin's lymphoma

Therapies

Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Bleomycin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.